Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycin.

Thaler, J; Denz, H; Dietze, O; Gastl, G; Ho, AD; Gattringer, C; Greil, R; Lechleitner, M; Huber, C; Huber, H; Leuk Res. 1989; 13(5): 377-383.

Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.

Hausmaninger, H; Lehnert, M; Steger, G; Sevelda, P; Michlmayr, G; Hehenwarter, W; Fridrik, M; Samonigg, H; Schiller, L; Manfreda, D; Onkologie. 1989; 12(5): 225-229.

Pirarubicin (4″-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study.

Scheithauer, W; Samonigg, H; Depisch, D; Schüller, J; Hausmaninger, H; Wiegele, J; Zielinsky, C; Stöger, H; Haider, K; Preis, P; Invest New Drugs. 1990; 8(2): 207-210.

[Cytologic molecular detection of oncogene expression: possibilities and prospects in hemato-oncology].

Greil, R; Fasching, B; Huber, H; Acta Med Austriaca. 1990; 17(1): 6-10.

PROGNOSTIC-SIGNIFICANCE OF TUMOR-CELL MORPHOMETRY, HISTOPATHOLOGY, AND CLINICAL-PARAMETERS IN ADVANCED OVARIAN-CARCINOMA

LUDESCHER, C; WEGER, AR; LINDHOLM, J; OEFNER, D; HAUSMANINGER, H; REITSAMER, R; MIKUZ, G INT J GYNECOL PATHOL. 1990; 9(4): 343-351.

Monoclonal antibody B-ly7: a sensitive marker for detection of minimal residual disease in hairy cell leukemia.

Thaler, J; Dietze, O; Faber, V; Greil, R; Gastl, G; Denz, H; Ho, AD; Huber, H; Leukemia. 1990; 4(3): 170-176.

A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor-alpha, interferon-gamma and interleukin 1.

Geissler, D; Gaggl, S; Möst, J; Greil, R; Herold, M; Dietrich, M; Eur J Immunol. 1990; 20(12):2591-2596

[Urticarial vasculitis as a symptom of Muckle-Wells syndrome?].

Grassegger, A; Greil, R; Feichtinger, J; Fritsch, P; Hintner, H; Hautarzt. 1991; 42(2):116-119

Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis.

Greil, R; Fasching, B; Loidl, P; Huber, H; Blood. 1991; 78(1):180-191

Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas.

Fridrik, MA; Hausmaninger, H; Michlmayr, G; Haidinger, R; Seewann, HL; Lehnert, M; Hematol Oncol. 1991; 9(4-5): 209-215.